| Popis: |
Purpose: Chest physiotherapy is an important tool in the treatment of bronchiectasis. High frequency chest wall oscillation (HFCWO) is techniques designed to create a global percussion of the lung which removes secretions and probably clears the peripheral bronchial tree. We purpose the comparison between a existing machine ( SmartVest ) and a novel machine ( RespIn 11). Methods: Sixty patients were randomized to three groups : a group was treated with SmartVest, a group with RespIn 11 and a group with pharmacological therapy alone. Primary outcome measures included exacerbations 3,6 and 12 months after the end of treatment. Secondary outcome measures were pulmonary function testing, arterial blood gas analysis(ABG), and hematological examinations, cough, dyspnea, health and quality of life scores ( Bronchiectasis Health Questionnaire[BHQ], Breathlessness, Cough, and Sputum Scale[BCSS], COPD Assessment Test[CAT], Leicester Cough Questionnaire[LCT] ).A 5-point Likert scale was used to evaluate patients preference. Results: Both patients in the HFCWO groups showed a significant improvement in the tests of dyspnea, cough and health and quality of life score evaluations (BHQ, BCSS, CAT, LCT) compared to the control group, but not in pulmonary function tests and ABG. Only RespIn 11 reduced exacerbations in comparison with control group. RespIn 11 had a greater score regarding patients preference. Conclusions: The two machines improve health and quality of life scores in patients with bronchiectasis. RespIn 11 demonstrated also a significant lowering of exacerbations and a better acceptance. |
